Physician profile
Herbert A Strunk
NPI 1861448649
$13,712.79
in general payments reported to CMS, 2019-2025
48 companies · $2,020 in 2025
The $2,020 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,863 · 2020: $1,766 · 2021: $1,734 · 2022: $1,636 · 2023: $2,359 · 2024: $2,334 · 2025: $2,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,713.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,822.35 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,419.64 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $1,224.76 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Novartis Pharmaceuticals Corporation | $1,170.03 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,000.29 | 2019-2024 | Xarelto |
| Amgen INC. | $815.84 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $790.58 | 2019-2025 | |
| Boston Scientific Corporation | $752.61 | 2022-2025 | Watchman Flx, Watchman Access System |
| Esperion Therapeutics, INC. | $679.52 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $615.35 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $526.77 | 2019-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $337.80 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $303.50 | 2019-2024 | |
| Irhythm Technologies, INC. | $293.51 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $212.33 | 2021-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $167.09 | 2025 | Attruby |
| Atricure, INC. | $162.02 | 2020-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Lexicon Pharmaceuticals, INC. | $126.43 | 2023-2024 | Inpefa |
| Lundbeck LLC | $121.76 | 2019-2020 | |
| Amarin Pharma, INC. | $117.98 | 2020-2022 | |
| Daiichi Sankyo INC. | $113.38 | 2019-2023 | Injectafer |
| Lilly USA, LLC | $99.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $75.98 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $60.47 | 2019-2024 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $54.32 | 2024 | Arcalyst |
| Novo Nordisk INC | $52.07 | 2021 | |
| Celgene Corporation | $48.51 | 2024 | Camzyos |
| Abbott Laboratories | $47.00 | 2022 | |
| Kestra Medical Technology Services, INC. | $44.15 | 2024 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $37.78 | 2025 | Onpattro |
| Kiniksa Pharmaceuticals, LTD. | $35.10 | 2023 | Arcalyst |
| Braemar Manufacturing, LLC | $33.07 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $32.65 | 2024 | Uptravi, Opsumit |
| Baxter Healthcare | $30.51 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Altathera Pharmaceuticals LLC | $29.92 | 2025 | Sotalol Hydrochloride |
| Vital Connect, INC | $29.30 | 2023 | Vitalpatch Rtm |
| Abiomed | $27.76 | 2025 | |
| G Medical Diagnostic Services, INC. | $25.06 | 2022 | |
| Medtronic, INC. | $24.01 | 2025 | Linq II |
| Davol INC. | $23.42 | 2021 | |
| Biotronik INC. | $21.51 | 2022 | |
| Vifor Pharma, INC. | $19.24 | 2019 | |
| Agepha Pharma Fz LLC | $17.45 | 2025 | Lodoco |
| Inspire Medical Systems, INC. | $17.11 | 2023 | Inspire |
| Philips North America LLC | $14.76 | 2023 | |
| Cvrx, INC. | $14.50 | 2022 | |
| Bardy Diagnostics, INC. | $13.37 | 2022 | |
| Gilead Sciences, INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Strunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.